Ceruloplasmin (glycosylphosphatidylinositol-linked ferroxidase associated with normal astrocytes) can also be secreted by glioma cells, where its function is unknown. Ceruloplasmin is not only present in glioma cells and in human glioma specimens but also is enriched in highly malignant glioma stem-like cells. Hyaluronan is a large extracellular glycosaminoglycan that enhances malignant glioma behaviors by interacting with CD44 receptors and by downstream activation of signaling proteins and transporters associated with malignancy. We examined the relationship between hyaluronan and ceruloplasmin expression in glioma stem-like cells. Antagonism of hyaluronan interactions with short-fragment hyaluronan oligomers decreased ceruloplasmin expression in parental and stem-like glioma cells in vivo and in cell culture, implying that hyaluronan regulates ceruloplasmin expression. Further gain and loss-of-function studies are needed to fully define the relationship between hyaluronan and ceruloplasmin, and ceruloplasmin's effect on malignant behaviors.
Fortna RR, Watson HA, Nyquist SEGlycosyl phosphatidylinositol-anchored ceruloplasmin is expressed by rat Sertoli cells and is concentrated in detergent-insoluble membrane fractionsBiol Reprod.1999;61:1042-1049.
2.
Klomp LW, Gitlin JDExpression of the ceruloplasmin gene in the human retina and brain: implications for a pathogenic model in aceruloplasminemia. Hum Mol Genet . 1996;5:1989-1996.
3.
Patel BN, David S.A novel glycosylphosphatidylinositol-anchored form of ceruloplasmin is expressed by mammalian astrocytes. J Biol Chem. 1997 ;272:20185-20190.
4.
Patel BN, Dunn RJ, David S.Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain. J Biol Chem. 2000;275:4305-4310.
5.
Salzer JL, Lovejoy L., Linder MC, et al. Ran-2, a glial lineage marker, is a GPI-anchored form of ceruloplasmin . J Neurosci Res. 1998;54:147-157.
6.
Park YS, Suzuki K., Taniguchi N., et al. Glutathione peroxidase-like activity of caeruloplasmin as an important lung antioxidant. FEBS Lett. 1999 ;458:133-136.
7.
Hellman NE, Gitlin JDCeruloplasmin metabolism and function. Annu Rev Nutr. 2002;22:439-458.
8.
Messerschmidt A., Rossi A., Ladenstein R., et al. X-ray crystal structure of the blue oxidase ascorbate oxidase from zucchini. Analysis of the polypeptide fold and a model of the copper sites and ligands. J Mol Biol.1989;206:513-529.
9.
Osaki S., Johnson DA, Frieden E.The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem. 1966;241:2746-2751.
10.
Osaki S., Johnson DA, Frieden E.The mobilization of iron from the perfused mammalian liver by a serum copper enzyme, ferroxidaseI. J Biol Chem. 1971;246:3018-3023.
11.
Bielli P., Calabrese L.Structure to function relationships in ceruloplasmin: a `moonlighting' protein . Cell Mol Life Sci. 2002;59:1413-1427.
12.
Laurell CB, Kullander S., Thorell J.Effect of administration of a combined estrogen-progestin contraceptive on the level of individual plasma proteins. Scand J Clin Lab Invest. 1968;21:337-343.
13.
Hough CD, Cho KR, Zonderman AB, et al. Coordinately up-regulated genes in ovarian cancer. Cancer Res. 2001;61:3869-3876.
14.
Kunapuli SP , Singh H., Singh P., et al. Ceruloplasmin gene expression in human cancer cells. Life Sci. 1987;40:2225-2228.
15.
Stassar MJ, Devitt G., Brosius M., et al. Identification of human renal cell carcinoma associated genes by suppression subtractive hybridization. Br J Cancer. 2001;85:1372-1382.
16.
Manjula S., Aroor AR, Raja A., et al. Elevation of serum ceruloplasmin levels in brain tumours. Acta Neurol Scand. 1992;86: 156-158.
17.
Conley L., Geurs TL, Levin LATranscriptional regulation of ceruloplasmin by an IL-6 response element pathway . Brain Res Mol Brain Res. 2005;139:235-241.
18.
di Patti MC , Persichini T., Mazzone V., et al. Interleukin-1beta up-regulates iron efflux in rat C6 glioma cells through modulation of ceruloplasmin and ferroportin-1 synthesis. Neurosci Lett. 2004;363:182-186.
19.
Knapp J., Olson L., Tye S., et al. Case of desmoplastic infantile ganglioglioma secreting ceruloplasmin . J Child Neurol. 2005;20:920-924.
20.
Al-Hajj M., Clarke MFSelf-renewal and solid tumor stem cells. Oncogene. 2004;23:7274-7282.
21.
Caussinus E. , Hirth F.Asymmetric stem cell division in development and cancer. Prog Mol Subcell Biol. 2007;45:205-225.
22.
Singh SK, Clarke ID, Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63:5821-5828.
Toole BPHyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4:528-539.
26.
Ranuncolo SM , Ladeda V., Specterman S., et al. CD44 expression in human gliomas. J Surg Oncol. 2002;79:30-35; discussion 35-36.
27.
Bouvier-Labit C., Liprandi A., Monti G., et al. CD44H is expressed by cells of the oligodendrocyte lineage and by oligodendrogliomas in humans. J Neurooncol. 2002;60:127-134.
28.
Toole BPHyaluronan in morphogenesis. Semin Cell Dev Biol. 2001;12:79-87.
29.
Knudson W., Chow G., Knudson CBCD44-mediated uptake and degradation of hyaluronan. Matrix Biol. 2002;21:15-23.
30.
Goodell MA, Brose K., Paradis G., et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med. 1996;183:1797-1806.
31.
Kondo T., Setoguchi T., Taga T.Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A. 2004;101:781-786.
32.
Galli R., Binda E., Orfanelli U., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64:7011-7021.
33.
Zeng C., Toole BP, Kinney SD, et al. Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer. 1998;77:396-401.
34.
Muir D., Johnson J., Rojiani M., et al. Assessment of lamininmediated glioma invasion in vitro and by glioma tumors engrafted within rat spinal cord. J Neurooncol . 1996;30:199-211.
35.
Gilg AG, Tye SL, Tolliver LB, et al. Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitorsClin Cancer Res.2008;14: 1804-1813.
36.
Bao S., Wu Q., McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756-760.
37.
Liu G., Yuan X., Zeng Z., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006 ;5:67.
38.
Lo HW, Day CP, Hung MCCancer-specific gene therapy. Adv Genet. 2005 ;54:235-255.
39.
Lee CM, Lo HW, Shao RP, et al. Selective activation of ceruloplasmin promoter in ovarian tumors: potential use for gene therapy. Cancer Res. 2004;64:1788-1793.
40.
Kluger HM, Kluger Y., Gilmore-Hebert M., et al. cDNA microarray analysis of invasive and tumorigenic phenotypes in a breast cancer model. Lab Invest. 2004 ;84:320-331.
41.
Kwok JC, Richardson DRThe iron metabolism of neoplastic cells: alterations that facilitate proliferation ? Crit Rev Oncol Hematol. 2002;42:65-78.
42.
Elstner A., Holtkamp N., von Deimling A.Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells . Clin Exp Metastasis. 2007;24:57-66.
43.
Kato M., Seki N., Sugano S., et al. Identification of sonic hedgehog-responsive genes using cDNA microarray. Biochem Biophys Res Commun. 2001 ;289:472-478.
44.
Bar EE, Chaudhry A., Lin A., et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells. 2007:2007-0166.
45.
Ghatak S., Misra S., Toole BPHyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway . J Biol Chem. 2002;277:38013-38020.
46.
Itano N., Atsumi F., Sawai T., et al. Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. Proc Natl Acad Sci U S A. 2002;99:3609-3614.
47.
Sohara Y., Ishiguro N., Machida K., et al. Hyaluronan activates cell motility of v-Src-transformed cells via Ras-mitogenactivated protein kinase and phosphoinositide 3-kinase-Akt in a tumor-specific manner. Mol Biol Cell. 2001;12:1859-1868.
48.
Ward JA, Huang L., Guo H., et al. Perturbation of hyaluronan interactions inhibits malignant properties of glioma cells. Am J Pathol. 2003;162:1403-1409.
49.
Dehnhardt M. , Zoriy MV, Khan Z., et al. Element distribution is altered in a zone surrounding human glioblastoma multiforme. J Trace Elem Med Biol. 2008;22:17-23.
50.
Brem S., Grossman SA, Carson KA, et al. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol. 2005 ;7:246-253.
51.
Donate F., Juarez JC, Burnett ME, et al. Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224). Br J Cancer. 2008;98:776-783.
52.
Lowndes SA, Harris ALThe role of copper in tumour angiogenesisJ Mammary Gland Biol Neoplasia.2005;10:299-310.
53.
Mazumder B., Fox PLDelayed translational silencing of ceruloplasmin transcript in gamma interferon-activated U937 monocytic cells: role of the 3' untranslated region. Mol Cell Biol. 1999;19:6898-6905.
54.
Mukhopadhyay CK, Mazumder B., Fox PLRole of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiencyJ Biol Chem.2000;275: 21048-21054.
55.
Das D., Tapryal N., Goswami SK, et al. Regulation of ceruloplasmin in human hepatic cells by redox active copper: identification of a novel AP-1 site in the ceruloplasmin gene . Biochem J. 2007;402:135-141.
56.
Comerford KM , Wallace TJ, Karhausen J., et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002;62:3387-3394.
57.
Keith B., Simon MCHypoxia-inducible factors, stem cells, and cancer. Cell. 2007;129:465-472.
58.
Irie N., Matsuo T., Nagata I.Protocol of radiotherapy for glioblastoma according to the expression of HIF-1 . Brain Tumor Pathol. 2004;21:1-6.
59.
Lee KH, Yun SJ, Nam KN, et al. Activation of microglial cells by ceruloplasmin. Brain Res. 2007;1171:1-8.
60.
Sarkaria JN , Carlson BL, Schroeder MA, et al. Use of an ortho-topic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response. Clin Cancer Res. 2006;12:2264-2271.
